Christoph Huels is responsible for the corporate innovation strategy and the technology foresight at Merck KGaA, Darmstadt, Germany. He is experienced in different businesses at Merck in Healthcare as well as Performance Materials (specialty chemicals). Including operational excellence in R&D, licensing, bio-partnering as well as the Corporate Venture Fund of Merck. Before joining Merck in 2008, he was CEO of Protagen AG, a German biotech company focussing on high value services in protein analysis especially under GMP, tool and software development for R&D in proteomics and the development of diagnostics based on a technology platform around protein biochips. He managed there several rounds of financing for the development of diagnostics as well as the build-up of a profitable service business in protein analysis. From 1999 to 2001 Christoph was responsible for project and portfolio management at Azupharma GmbH and CoKG, the German subsidiary of the Generics business of the Novartis group. He started his professional career in 1994 at Hoechst AG. After two years in the pharma division of Hoechst (today Sanofi) in Rheumatology/Immunology early phase drug development, he was working in increasing responsibility on projects in cell adhesion, protein evolution and RNA-splicing in the Central Research department. Christoph received his PhD in Biology from the Johannes-Gutenberg-University in Mainz at the Institute of Immunology.